Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).